Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12828281 | 0.82 | KMT2A (0.40) | NAMPTRAB9AKMT2AMEN1TSHR | |
| SCHEMBL12828537 | 0.81 | MEN1 (0.34) | RAB9AKMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL12828868 | 0.79 | SMN1; SMN2 (0.58) | NAMPTKMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL12828993 | 0.78 | RAB9A (0.44) | NAMPTRAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL12828280 | 0.78 | RAB9A (0.55) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12828534 | 0.77 | MEN1 (0.37) | KMT2AMEN1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL12828538 | 0.76 | SMN1; SMN2 (0.38) | NAMPTKMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL12828886 | 0.76 | NAMPT (0.48) | NAMPTRAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12828997 | 0.75 | MAPT (0.49) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12828600 | 0.75 | RAB9A (0.43) | RAB9ASMN1; SMN2ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | NAMPT 1189/4885RAB9A 2013/4885KMT2A 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.